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TX-004HR Improves Sexual Function as Measured by the Female Sexual
Function Index in Postmenopausal Women With Vulvar and Vaginal
Atrophy: The REJOICE Trial
Sheryl A. Kingsberg, PhD,1 Leonard Derogatis, PhD,2 James A. Simon, MD,3 Ginger D. Constantine, MD,4
Shelli Graham, PhD,5 Brian Bernick, MD,5 Gina Gasper,5 and Sebastian Mirkin, MD5
ABSTRACT
Introduction: TX-004HR is an investigational, applicator-free, vaginal soft gel capsule containing low-dose
solubilized 17b-estradiol. The phase 3, randomized, double-blinded, placebo-controlled, multicenter
REJOICE trial has shown TX-004HR to be safe and effective for the treatment of moderate to severe dys-
pareunia in postmenopausal women with vulvar and vaginal atrophy (VVA).
Aim: To evaluate the effect of TX-004HR on female sexual dysfunction in postmenopausal women with VVA.
Methods: The REJOICE study compared the effects of 12-week treatment with TX-004HR (4, 10, or 25 mg)
with placebo in postmenopausal women (40e75 years old) with VVA and a most bothersome symptom of
moderate to severe dyspareunia. Changes in the percentage of superﬁcial and parabasal cells, vaginal pH, and
dyspareunia were measured as co-primary end points. Female sexual dysfunction was evaluated as a secondary
end point using the Female Sexual Function Index (FSFI) patient self-report inventory.
Main Outcome Measures: Changes from baseline to week 12 in total and individual domain FSFI scores for
each TX-004HR dose were compared with those for placebo.
Results: All three TX-004HR doses increased the baseline total FSFI score after 12 weeks, with 10 mg (P < .05)
and 25 mg (P ¼ .0019) having a signiﬁcantly greater effect than placebo. A similar trend was observed for the
individual FSFI domains, with 10 and 25 mg signiﬁcantly improving baselines scores for pain and lubrication at
12 weeks (P  .015 for all vs placebo). Changes from baseline to week 12 in arousal (P ¼ .0085) and satisfaction
(P ¼ .0073) were signiﬁcantly greater for TX-004HR 25 mg vs placebo. All three TX-004HR doses were
comparable to placebo in their effect on desire and orgasm.
Conclusion: TX-004HR improved FSFI scores in a dose-dependent manner. The observed improvements in
sexual function suggest that TX-004HR is a promising treatment option for postmenopausal VVA with a po-
tential added beneﬁcial effect on female sexual dysfunction.
J Sex Med 2016;13:1930e1937. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the
International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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INTRODUCTION
Vulvar and vaginal atrophy (VVA) is a chronic, progressive
condition that affects up to 69% of postmenopausal women.1
Considered a symptom of genitourinary syndrome of meno-
pause,2 VVA is characterized by the thinning, drying, and loss of
elasticity of the vaginal epithelium3 and clinically manifests as
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symptoms of vaginal dryness, irritation, dysuria, and pain (dys-
pareunia) or bleeding with sexual activity.4
VVA has a negative impact on women’s quality of life and has
been associated with female sexual dysfunction (FSD). The Real
Women’s Views of Treatment Options for Menopausal Vaginal
Changes (REVIVE) study reported that VVA symptoms inter-
fered with enjoyment of sex in 59% of respondents and 12% of
women without a partner reported they were not seeking a sexual
partner because of their VVA symptoms.5 Women respondents
in the Clarifying Vaginal Atrophy’s Impact on Sex and Re-
lationships (CLOSER) survey attributed loss of intimacy (58%)
and libido (64%) to vaginal dryness.6 The Menopause Epide-
miology study found that VVA was almost four times more likely
in women with FSD than in women without FSD.7
TX-004HR (TherapeuticsMD Inc, Boca Raton, FL, USA) is
an investigational, applicator-free, vaginal-mucosal adhesive,
soft gel capsule containing low-dose solubilized 17b-estradiol8
designed to provide relief from postmenopausal symptoms of
VVA, including dyspareunia and vaginal dryness, with negligible
to very low systemic absorption. The 12-week, randomized,
double-blinded, phase 3 REJOICE trial recently demonstrated
that 4-, 10-, and 25-mg doses of TX-004HR were efﬁcacious in
treating VVA due to menopause. Speciﬁcally, TX-004HR
signiﬁcantly improved the percentage of superﬁcial and para-
basal cells and vaginal pH,8 with negligible to very low absorption
of estradiol (average levels did not increase with 4- and 10-mg
doses and remained within the normal postmenopausal range 
30 pg/mL with the 25-mg dose).9 Importantly, all three doses
signiﬁcantly improved postmenopausal symptoms of VVA,
including dyspareunia, vaginal dryness, and vaginal itching and
irritation compared with placebo. Signiﬁcant improvements in
vaginal physiology and dyspareunia were noted as early as 2 weeks
and were maintained over the 12-week study period.8 Based on
the previously established association between postmenopausal
VVA and sexual function,5e7 TX-004HR also is expected to have
a beneﬁcial effect on sexual function.
AIM
The aim of this study was to evaluate the effects of 12-week
treatment with TX-004HR (at doses of 4, 10, or 25 mg) or
placebo on FSD, as assessed using the Female Sexual Function
Index (FSFI), in postmenopausal women with VVA and the
most bothersome symptom of moderate to severe dyspareunia.
METHODS
Study Design
The REJOICE study was a 12-week, multicenter, random-
ized, double-blinded, parallel-group trial comparing the safety
and efﬁcacy of 4-, 10-, and 25-mg doses of TX-004HR with
placebo in postmenopausal women diagnosed with VVA.
Complete details on the REJOICE study design have been
previously reported.8 Brieﬂy, study participants were randomized
1:1:1:1 to TX-00HR 4, 10, or 25 mg or placebo.8 TX-004HR is
a small, tear-shaped, light pink soft gel capsule containing three
different doses of 17b-estradiol (4, 10, or 25 mg). To allow for a
double-blinded study design, the TX-004HR and placebo cap-
sules were similar in appearance and, with the exception of the
17b-estradiol, were formulated using the same excipients,
including Miglyol 812 (IOI Oleo GmbH, Hamburg, Germany),
a fractionated coconut oil (medium-chain triglycerides NF).
Clinical evaluation was performed during the washout period
(6e14 weeks before the start of the study), screening
period (6 weeks), randomization at baseline, active treatment
period (weeks 2, 6, and 8), end of treatment or early termination
(12 weeks), and post-study follow-up at week 14.8 Women self-
administered one capsule daily, intravaginally for 2 weeks, fol-
lowed by biweekly dosing (3e4 days apart) for 10 weeks.8
Efﬁcacy assessment included changes from baseline to week 12
in the co-primary end points of the percentage of superﬁcial cells,
percentage of parabasal cells, vaginal pH, and patient-reported
most bothersome symptom of moderate to severe dyspareunia.8
Additional secondary end points included change from baseline
in the severity of vaginal dryness and vulvar and/or vaginal
itching or irritation and in the visual evaluation of the vaginal
mucosa. FSD also was assessed as a secondary end point at
12 weeks using the FSFI.
The REJOICE trial was designed, conducted, and monitored
in accordance with the sponsor’s procedure, Good Clinical
Practice guidelines, and the principles speciﬁed in the Declara-
tion of Helsinki. The study protocol was approved by the
institutional review board at all participating centers. Written
informed consent was obtained for all study participants.
Study Population
The inclusion and exclusion criteria for the REJOICE
study have been previously reported.8 Postmenopausal women
(age 40e75 years; body mass index  38 kg/m2) with no more
than 5% superﬁcial cells on a vaginal cytological smear, vaginal
pH higher than 5.0, and the most bothersome symptom of
moderate to severe dyspareunia due to menopause were eligible
to participate in the trial. In addition, women had to be sexually
active (with vaginal penetration) and anticipate sexual activity
during the trial period. Postmenopausal women with an intact
uterus were required to have an acceptable result from an
endometrial biopsy examination conducted at screening.
Women were not permitted to take any oral products con-
taining estrogen, progestin, androgen, or selective estrogen re-
ceptor modulators within 8 weeks; transdermal hormones within
4 weeks; vaginal hormones (rings, creams, gels) within 4 weeks;
intrauterine progestins within 8 weeks; progestin implants or
injectables or estrogen pellets or injectables within 6 months;
vaginal lubricants or moisturizers within 7 days before vaginal
pH assessment during screening; investigational drugs within
60 days; or an intrauterine device within 12 weeks before
screening.
J Sex Med 2016;13:1930e1937
Effect of TX-004HR on Female Sexual Function 1931
Women with a history of or active clinically important medical
diseases (ie, hypersensitivity to estrogens, endometrial hyperplasia,
undiagnosed vaginal bleeding, myocardial infarction, or ischemic
heart disease) that could potentially confound the study or be
detrimental to their well-being were excluded. Women were
ineligible to participate in the study if they had a history of
estrogen-dependent neoplasia, breast cancer, melanoma, or any
gynecologic cancer at any time; a recent history of known alcohol
or drug abuse; a current history of heavy smoking (>15 cigarettes/
d) or use of e-cigarettes; and a history of sexual abuse or spousal
abuse that (in the opinion of the investigator) could interfere with
their ability to assess vaginal pain with sexual activity.
Concomitant medications (except for investigational drugs;
estrogen, progestin, androgen, or selective estrogen receptor
modulators containing medications other than TX-004HR; and
prescription and non-prescription medications or remedies for
VVA, including vaginal lubricants and moisturizers) were
permitted and recorded in diaries during the study period.
MAIN OUTCOME MEASURES
The FSFI is a brief, valid, reliable, multidimensional, self-
report instrument for assessing sexual function during the past
4 weeks.10 The FSFI consists of 19 questions categorized into six
domains of sexual function (desire, arousal, lubrication, orgasm,
satisfaction, and pain).10 The FSFI questionnaire was adminis-
tered to all study participants, except for those participating in
the pharmacokinetic sub-study, at baseline and at week 12.
Changes in total and individual domain FSFI scores from base-
line to week 12 were recorded as a secondary end point of the
REJOICE trial.
Scores for each FSFI domain were calculated by adding the
scores for the individual domain questions and multiplying by
the domain factor (0.6 for desire, 0.3 for arousal and lubrication,
and 0.4 for orgasm, satisfaction, and pain). Each FSFI domain is
graded using a scale of 0 to 6, with the exception of the desire
domain, which is graded on a scale of 1.2 to 6. The total FSFI
score is deﬁned as the sum of the individual domain scores and
ranges from a minimum score of 2 to a maximum score of 36
points. Sexual dysfunction was deﬁned as a total FSFI score no
higher than 26.55 of a maximum possible score of 36.11
Statistical Analyses
FSFI analyses were conducted for the modiﬁed intent-to-treat
population, which consisted of subjects who received treatment
to which they were randomized, had baseline values for all four
co-primary end points, and at least one post-baseline value for
any of the four co-primary end points no more than 7 days after
the last dose. Changes from baseline in the total and individual
domain FSFI scores were summarized descriptively for each
treatment group. Analysis of covariance models were used to
compare changes in total and individual domain FSFI scores
from baseline to week 12 for each TX-004HR dose vs placebo,
with baseline as the covariate.
RESULTS
Participant Disposition and Baseline Characteristics
In total, 764 women were eligible to participate in the
REJOICE study, of which 704 (92%) completed the study. The
FSFI questionnaire was administered to 692 of the 764 post-
menopausal women participating in the REJOICE trial. Women
were randomized to TX-004HR 4 mg (n¼ 173), 10 mg (n¼ 172),
25 mg (n ¼ 172), or placebo (n ¼ 175).
Demographics and baseline characteristics of the women who
completed the FSFI were comparable among the four treatment
groups (Tables 1 and 2). Most women were white with mean age
of 59 years and a mean body mass index of 27 kg/m2. The mean
total FSFI score was 14.8 at baseline.
Sexual Function
Numerical improvements from baseline to week 12 in total
and individual domain FSFI scores were observed for all treat-
ment groups, including placebo (Table 2). Compared with pla-
cebo, the improvement in total FSFI score from baseline to
12 weeks was signiﬁcantly greater with TX-004HR 10- and
25-mg doses (Figure 1).
Baseline scores for FSFI domains of lubrication and pain
signiﬁcantly improved after 12-week treatment with TX-004HR
10 and 25 mg compared with placebo (Figure 2). Statistically
signiﬁcant improvements in FSFI domains of arousal and satis-
faction also were seen with TX-004HR 25 mg vs placebo. No
statistically signiﬁcant differences between TX-004HR 4 mg and
Table 1. Demographics and baseline characteristics of Female Sexual Function Index study group
TX-004HR 4 mg
(n ¼ 173)
TX-004HR 10 mg
(n ¼ 172)
TX-004HR 25 mg
(n ¼ 172)
Placebo
(n ¼ 175)
Age (y), mean ± SD 60.0 ± 5.73 58.5 ± 6.22 58.8 ± 6.27 59.3 ± 6.09
Race, n (%)
White 149 (86.1) 150 (87.2) 149 (86.6) 146 (83.4)
Black or African American 20 (11.6) 20 (11.6) 22 (12.8) 23 (13.1)
Asian 3 (1.7) 2 (1.2) 1 (0.6) 1 (0.6)
BMI (kg/m2), mean ± SD 26.3 ± 4.77 26.7 ± 4.69 26.5 ± 4.70 26.6 ± 4.52
BMI ¼ body mass index.
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Table 2. FSFI scores at baseline and week 12
FSFI score
TX-004HR 4 mg
(n ¼ 173)
TX-004HR 10 mg
(n ¼ 172)
TX-004HR 25 mg
(n ¼ 172)
Placebo
(n ¼ 175)
Total
Baseline, n 173 170 172 174
Mean ± SD 14.8 ± 6.1 15.8 ± 6.2 14.2 ± 6.2 14.4 ± 6.6
Range 2e28.2 2e32.2 2e29.1 2e33.8
Week 12, n 153 154 156 159
Mean ± SD 22.6 ± 8.4 24.8 ± 7.6 24.8 ± 7.6 22 ± 8.5
Range 2e36 2.3e35.4 3.2e36 2e35.6
Arousal
Baseline, n 173 170 172 175
Mean ± SD 2.8 ± 1.4 2.9 ± 1.4 2.7 ± 1.5 2.7 ± 1.4
Range 0e5.7 0e6 0e6 0e6
Week 12, n 154 154 157 159
Mean ± SD 3.6 ± 1.6 4.1 ± 1.5 4.1 ± 1.4 3.6 ± 1.5
Range 0e6 0e6 0e6 0e6
Desire
Baseline, n 173 170 172 175
Mean ± SD 2.6 ± 1.0 2.7 ± 1.2 2.6 ± 1.1 2.7 ± 1.1
Range 1.2e6 1.2e6 1.2e6 1.2e6
Week 12, n 154 154 157 159
Mean ± SD 3.3 ± 1.1 3.5 ± 1.1 3.5 ± 1.1 3.3 ± 1.2
Range 1.2e6 1.2e6 1.2e6 1.2e6
Lubrication
Baseline, n 173 170 172 175
Mean ± SD 2.1 ± 1.2 2.2 ± 1.2 2.0 ± 1.2 2.0 ± 1.3
Range 0e6 0e5.7 0e5.1 0e5.4
Week 12, n 153 154 156 159
Mean ± SD 3.9 ± 1.8 4.4 ± 1.6 4.3 ± 1.7 3.6 ± 1.8
Range 0e6 0e6 0e6 0e6
Orgasm
Baseline, n 173 170 172 175
Mean ± SD 2.7 ± 1.8 2.9 ± 1.7 2.4 ± 1.7 2.4 ± 1.7
Range 0e6 0e6 0e6 0e6
Week 12, n 153 154 156 159
Mean ± SD 3.8 ± 1.9 4.1 ± 1.8 4.1 ± 1.7 3.7 ± 2.0
Range 0e6 0e6 0e6 0e6
Pain
Baseline, n 173 170 172 175
Mean ± SD 1.6 ± 1.1 1.8 ± 1.2 1.7 ± 1.2 1.7 ± 1.2
Range 0e4.4 0e5.6 0e5.6 0e5.6
Week 12, n 154 154 156 159
Mean ± SD 3.8 ± 2.0 4.3 ± 1.9 4.2 ± 2.0 3.6 ± 1.9
Range 0e6 0e6 0e6 0e6
Satisfaction
Baseline, n 173 170 172 174
Mean ± SD 2.9 ± 1.4 3.2 ± 1.4 2.9 ± 1.4 2.9 ± 1.5
Range 0.8e6 0.8e6 0.8e6 0.8e6
Week 12, n 154 154 157 159
Mean ± SD 4.2 ± 1.5 4.4 ± 1.4 4.6 ± 1.4 4.1 ± 1.5
Range 0.8e6 0.8e6 0.8e6 0.8e6
FSFI ¼ Female Sexual Function Index.
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placebo were observed. All three TX-004HR doses were com-
parable to placebo in their effect on the FSFI domains of desire
and orgasm (Figure 2).
DISCUSSION
In this analysis of the REJOICE trial, TX-004HR improved
sexual function in postmenopausal women with moderate
to severe VVA and dyspareunia. After 12 weeks, all three
TX-004HR doses increased the average baseline total FSFI score
(least squares [LS] mean) by a range of 7.91 to 10.28 points, with
TX-004HR 10 and 25 mg having statistically signiﬁcant im-
provements vs placebo (LS mean change ¼ 7.46). Compared
with placebo, TX-004HR 25 mg signiﬁcantly improved baseline
scores for FSFI domains of pain, lubrication, arousal, and satis-
faction, and TX-004HR 10 mg improved FSFI pain and lubri-
cation domain scores.
These results extend the observations of the primary data from
the REJOICE trial, in which all doses of TX-004HR improved
vaginal physiology and dyspareunia as early as 2 weeks after
initiating TX-004HR treatment.8 In addition, improvements in
vaginal dryness with TX-004HR were initially seen as soon as
week 2 with 10- and 25-mg doses and at week 6 with 4 mg. All
three TX-004HR doses were well tolerated, with no clinically
signiﬁcant differences in adverse events compared with the pla-
cebo group. The most commonly reported treatment emergent
adverse events were headache, vaginal discharge, nasopharyngitis,
and vulvovaginal pruritus, with the incidence for each being
numerically lower with TX-004HR than with placebo. Study
discontinuation owing to adverse events also was low (1.8% of
women). A complete description of the TX-004HR safety data
from the REJOICE study has been reported.8 Negligible to very
low systemic absorption of estradiol was seen with all doses of
TX-004HR, resulting in systemic estradiol levels within the
postmenopausal range.9
Of the six FSFI domains, TX-004HR had the greatest
effect on pain (LS mean change from baseline to week
12 ¼ 2.17e2.55; Figure 2B) followed by lubrication (LS mean
change from baseline to week 12 ¼ 1.83e2.30; Figure 2C). This
is consistent with the clinically signiﬁcant decrease in the severity
of dyspareunia with TX-004HR (decreased by 55%e65%), in
addition to improvements in vaginal dryness (decreased by
54%e63%) and vulvar and/or vaginal irritation or itching
(decreased by 67%) reported previously.8
Although a head-to-head comparison was not performed, the
magnitude of change in total and individual domain FSFI scores
with all three TX-004HR doses was comparable to those re-
ported for ospemifene, which was evaluated in postmenopausal
women with VVA.12 Women participating in the two studies
were considered to have sexual dysfunction as noted by total
FSFI scores of 14.2 to 15.8 in this study and 19.8 in the
ospemifene study.12 After 12 weeks, the improvement in total
FSFI score with TX-004HR 4 mg (LS mean change ¼ 7.91),
10 mg (LS mean change ¼ 9.43), and 25 mg (LS mean
change ¼ 10.28) was numerically greater than that reported
for ospemifene (LS mean change ¼ 7.37 for dyspareunia
stratum).12
Notably, the two studies differed in the effect of placebo, which
was relatively greater in this study than that reported for ospemi-
fene.12 This is likely due to differences in allowed lubricant use
between the studies. Although lubricants were not permitted in
this study, the formulation for the placebo and TX-004HR vaginal
capsules contained Miglyol, a fractionated coconut oil that might
have lubricating properties. Thus, continuous exposure toMiglyol
with placebo could have contributed to the large placebo response
seen in this study. In contrast, lubricant use was allowed as needed
in the ospemifene study12 rather than on a continual basis, so the
placebo response would not be expected to be as great as that
reported in our study.
The signiﬁcant improvement in total FSFI and FSFI pain and
lubrication domain scores with higher TX-004HR doses, despite
the large placebo response, suggests TX-004HR has an added
positive effect on sexual function, a likely result of the
improvement in vaginal physiology and dyspareunia. Because
many factors, such as sexual desire, arousal, orgasm, woman’s
conﬁdence, and relationship status, associated with overall sexual
health are highly comorbid, continuous use of TX-004HR
would be expected to improve sexual dysfunction in post-
menopausal women with VVA. Although this would be consis-
tent with the reported association between postmenopausal VVA
and sexual dysfunction,5e7 longer-term clinical studies would be
needed to conﬁrm these initial hypotheses.
The generalizability of the ﬁndings might be limited by the
women being primarily white with a high body mass index (26 kg/
m2). Another limitation of this analysis is that the effect of TX-
004HR on sexual function with the FSFI was evaluated as a sec-
ondary end point of the REJOICE study. Despite being widely
used, the FSFI has not been validated in a population of post-
menopausal women with VVA, but rather in a mixed sample
population of women with female sexual arousal disorder,
Figure 1. Mean change from baseline to week 12 in total Female
Sexual Function Index10 score. *P < .05; †P ¼ .0019 vs placebo.
LS ¼ least squares.
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hypoactive sexual desire disorder, female sexual orgasm disorder,
dyspareunia or vaginismus, and multiple sexual dysfunctions.
Furthermore, the REJOICE study was designed according to the
U.S. Food and Drug Administration’s guidance for evaluating
estrogen-based treatments for VVA13 rather than FSD. However,
as previously stated, the improvements in total and individual
domain scores of the FSFI were comparable to those seen with
ospemifene, suggesting that TX-004HR could improve sexual
function in postmenopausal womenwith VVA.No FSFI data have
been reported for any of the low-dose vaginal estrogens approved in
the United States.
CONCLUSION
TX-004HR dose-dependently improved sexual function in
postmenopausal women with VVA participating in the phase 3,
Figure 2. Mean change from baseline to week 12 in scores for Female Sexual Function Index10 domains of (A) lubrication, (B) pain,
(C) arousal, (D) satisfaction, (E) desire, and (F) orgasm. *P¼ .0013; **P¼ .0003; ***P< .01; †P ¼ .015; ††P¼ .0085; †††P ¼ .0073 vs placebo.
FSFI ¼ Female Sexual Function Index; LS ¼ least squares.
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randomized, double-blinded, placebo-controlled REJOICE trial
as measured by the FSFI. All three TX-004HR doses and placebo
increased total FSFI and individual domain FSFI scores after
12 weeks, with 25 mg having the greatest effect compared with
placebo. In addition, the REJOICE trial reported signiﬁcant
improvement in the co-primary end points (percentage
of parabasal and superﬁcial cells and vaginal pH) for post-
menopausal VVA and reduced the severity of dyspareunia after 12
weeks of TX-004HR treatment, with signiﬁcant effects seen as
early as 2 weeks of treatment. The present FSFI data coupled with
improvement in vaginal physiology suggest that TX-004HR
could be a promising treatment option for VVA, with a poten-
tial added beneﬁt of improving FSD in postmenopausal women.
ACKNOWLEDGMENTS
The authors thank the investigators of the REJOICE Study
Group who participated in the collection of the FSFI data. The
authors also thank Harvey Kushner, PhD, for statistical analyses
and Disha Patel, PhD, of Precise Publications, LLC for medical
writing support, which was funded by TherapeuticsMD.
Corresponding Author: Sheryl A. Kingsberg, PhD, Mailstop
5034, 11100 Euclid Avenue, Cleveland, OH 44106, USA;
E-mail: Sheryl.Kingsberg@UHhospitals.org
Conﬂicts of Interest: Dr Kingsberg has served as a consultant for
TherapeuticsMD Inc, Novo Nordisk Inc, Pﬁzer Inc, Palatin,
Emotional Brain, Sprout Pharmaceuticals Inc, Valeant Pharma-
ceuticals Inc, Sermonix Pharmaceuticals Inc, Nuelle Inc, Apricus
Inc, and Materna. Dr Derogatis is a clinical trials investigator and
a member of the scientiﬁc advisory board for Palatin Pharma-
ceuticals, S1 Biopharam, Emotional Brain, Acerus, and Endo-
ceutics and has seved as an investigator for AbbVie Inc and
TherapeuticsMD. Dr Simon has served (within the past year) or
is currently serving as a consultant to or on the advisory boards of
AbbVie Inc, AMAG Pharmaceuticals Inc, Amgen Inc, Apotex
Inc, Ascend Therapeutics, JDS Therapeutics LLC, Merck & Co
Inc, Noven Pharmaceuticals Inc, Novo Nordisk, Nuelle Inc,
Perrigo Company PLC, Radius Health Inc, Regeneron Phar-
maceuticals Inc, Roivant Sciences Inc, Sanoﬁ SA, Sermonix
Pharmaceuticals Inc, Shionogi Inc, Sprout Pharmaceuticals,
Symbiotec Pharmalab, and TherapeuticsMD; has served (within
the past year) or is currently serving on the speaker’s bureaus of
Amgen Inc, Eisai Inc, Merck, Noven Pharmaceuticals Inc, Novo
Nordisk, and Shionogi Inc; in the past year has received or is
currently receiving grant or research support from AbbVie Inc,
Actavis PLC, Agile Therapeutics, Bayer Healthcare LLC, New
England Research Institute Inc, Novo Nordisk, Palatin Tech-
nologies, Symbio Research Inc, TherapeuticsMD; and is a
stockholder (direct purchase) of Sermonix Pharmaceuticals.
Dr Constantine consults to pharmaceutical companies, including
but not limited to TherapeuticsMD. Dr Bernick is a board
member and an employee of TherapeuticsMD with stock and
stock options. Dr Graham, Ms. Gasper, and Dr Mirkin are
employees of TherapeuticsMD with stock and stock options.
Funding: This study was funded TherapeuticsMD.
STATEMENT OF AUTHORSHIP
Category 1
(a) Conception and Design
Ginger Constantine, Brian Bernick, and Sebastian Mirkin
(b) Acquisition of Data
Leonard Derogatis and James A. Simon
(c) Analysis and Interpretation of Data
Sheryl A. Kingsberg, Leonard Derogatis, James A. Simon,
Ginger D. Constantine, Shelli Graham, Brian Bernick, Gina
Gasper, and Sebastian Mirkin
Category 2
(a) Drafting the Article
Sheryl A. Kingsberg, Leonard Derogatis, James A. Simon,
Ginger D. Constantine, Shelli Graham, Brian Bernick, and
Sebastian Mirkin
(b) Revising It for Intellectual Content
Sheryl A. Kingsberg, Leonard Derogatis, James A. Simon,
Ginger D. Constantine, Shelli Graham, Brian Bernick, Gina
Gasper, and Sebastian Mirkin
Category 3
(a) Final Approval of the Completed Article
Sheryl A. Kingsberg, Leonard Derogatis, James A. Simon,
Ginger D. Constantine, Shelli Graham, Brian Bernick, Gina
Gasper, and Sebastian Mirkin
REFERENCES
1. Gass ML, Cochrane BB, Larson JC, et al. Patterns and pre-
dictors of sexual activity among women in the hormone
therapy trials of the Women’s Health Initiative. Menopause
2011;18:1160-1171.
2. Portman DJ, Gass ML. Genitourinary syndrome of meno-
pause: new terminology for vulvovaginal atrophy from the
International Society for the Study of Women’s Sexual Health
and the North American Menopause Society. Menopause
2014;21:1063-1068.
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy.
Mayo Clin Proc 2010;85:87-94.
4. Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical
presentation, and treatment considerations. Clin Obstet
Gynecol 2015;58:476-491.
5. Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal
atrophy in postmenopausal women: ﬁndings from the REVIVE
(REal Women’s VIews of Treatment Options for Menopausal
Vaginal ChangEs) survey. J Sex Med 2013;10:1790-1799.
6. Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying Vaginal
Atrophy’s Impact on Sex and Relationships (CLOSER) survey:
emotional and physical impact of vaginal discomfort on North
American postmenopausal women and their partners.
Menopause 2014;21:137-142.
J Sex Med 2016;13:1930e1937
1936 Kingsberg et al
7. Levine KB,Williams RE, Hartmann KE. Vulvovaginal atrophy is
strongly associated with female sexual dysfunction among
sexually active postmenopausal women. Menopause 2008;
15:661-666.
8. Constantine GD, Simon JA, Pickar JH, et al. The REJOICE Trial:
a phase 3 randomized controlled trial evaluating the safety and
efﬁcacy of a novel vaginal estradiol softgel capsule for
symptomatic vulvar and vaginal atrophy (VVA). Poster pre-
sented at: 98th Annual Meeting and Expo of the Endocrine
Society; 2016; Boston, MA.
9. Archer DF, Constantine GD, Kushner H, et al. TX-004HR
vaginal estradiol effectively treats vulvar and vaginal atrophy
(VVA) with negligible to low systemic absorption. Poster
presented at: 98th Annual Meeting and Expo of the Endocrine
Society; 2016; Boston, MA.
10. Rosen R, Brown C, Heiman J, et al. The Female Sexual
Function Index (FSFI): a multidimensional self-report
instrument for the assessment of female sexual function.
J Sex Marital Ther 2000;26:191-208.
11. Wiegel M, Meston C, Rosen R. The Female Sexual Function
Index (FSFI): cross-validation and development of clinical
cutoff scores. J Sex Marital Ther 2005;31:1-20.
12. Constantine G, Graham S, Portman DJ, et al. Female sexual
function improved with ospemifene in postmenopausal
women with vulvar and vaginal atrophy: results of a random-
ized, placebo-controlled trial. Climacteric 2015;18:226-232.
13. Guidance for industry: estrogen and estrogen/progestin drug
products to treat vasomotor symptoms and vulvar and
vaginal atrophy symptoms—recommendations for clinical
evaluation. US Department of Health and Human Services,
Food and Drug Administration, Center for Drug Evaulation
and Research. Available at: www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm
071643.pdf. Published January 2003.
J Sex Med 2016;13:1930e1937
Effect of TX-004HR on Female Sexual Function 1937
